课题基金 / 基金详情

项目摘要

项目成果

ROBERT A SEDER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The major discovery this year are as follows. 1. Assessed the safety and efficacy L9LS is several Phase 2 clinical trials in Mali and Kenya in infants, young children and adults. 2. Demonstrated that affinity and cytolytic activity are the two major in vitro characteristics that predict in vivo protection by a monoclonal antibody against PfCSP 3. Demonstrated the role of Fc effector function for mediating protection in vivo by monoclonal antibodies against PfCSP 4. Developed multiple models to improve the potency of monoclonal antibodies against PfCSP. 5. Initiated development of a multi-stage vaccine against Pf.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.vaccine.2010.08.098
发表时间: 2010-10-21
期刊: VACCINE
影响因子: 5.5
作者: [Tewari, Kavita, Flynn, Barbara J., Boscardin, Silvia B., Kastenmueller, Kathrin, Salazar, Andres M., Anderson, Charles A., Soundarapandian, Velmurugan, Ahumada, Adriana, Keler, Tibor, Hoffman, Stephen L., Nussenzweig, Michel C., Steinman, Ralph M., Seder, Robert A.]
通讯作者: Seder, Robert A.
VACCINE DEVELOPMENT FOR TUBERCULOSIS
  • 批准号:
    7958684
  • 项目类别:
  • 资助金额:
    $5.57万
  • 财政年份:
    2009
  • 负责人:
    ROBERT A SEDER
  • 依托单位:
DNA VACCINATION FOR PREVENTION OF VIRAL, PARASITIC AND MYCOBACTERIAL INFECTION
Development Of A Vaccine For Leishmania Major Infection
Development Of A Vaccine For Leishmania Major Infection
海外基金